Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

  1. Gabriel Chodick
  2. Lilac Tene
  3. Tal Patalon
  4. Sivan Gazit
  5. Amir Ben Tov
  6. Dani Cohen
  7. Khitam Muhsen

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1001/jamanetworkopen.2021.15985
  2. ScreenIT

    SciScore for 10.1101/2021.01.27.21250612: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: We obtained ethical approval from Maccabi Healthcare Services Ethics Committee.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    We obtained ethical approval from Maccabi Healthcare Services Ethics Committee.
    Maccabi Healthcare
    suggested: None
    All analyses were done using IBM-SPSS Version 27 (Armonk, NY: IBM Corp) and R packages magrittr, readtext, dplyr, ggplot2, tidyverse, survival, and survminer.
    ggplot2
    suggested: (ggplot2, RRID:SCR_014601)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study also has limitations. In addition, in this database analysis we did not assess COVID-19 symptoms and complications and therefore we were unable to assess effectiveness in protecting against COVID-19. Unreported vaccination is another potential limitation; however, the total number of vaccinated individuals by 1/15/21 in our analysis accounts for approximately 25% [21] of the total number of vaccinated Israelis on 1/15/21 that is comparable to the market share of MHS, leaving little room for significant gap in data. In conclusion, in this analysis of large-scale real-world data, we showed approximately 51% effectiveness of BNT162b2 COVID-19 vaccine against PCR-confirmed SARS-CoV-2 infection 13-24 days after immunization with the first dose using the preceding 1-12 days as a reference. This estimate was consistent across age, sex, sector, or comorbidity, except for diabetes. These findings have global public health implications and open new horizons towards the control of COVID-19 pandemic and reducing the transmission of SARS-CoV-2. Global effort should accelerate COVID-19 vaccines deployment urgently.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.01.27.21250612v1 on medRxiv